Objective To observe the effects of Buyang Huanwu Decoction(BHD)on collateral circulation of patients with acute cerebral infarction(ACI)through transcranial Doppler sonography(TCD). Methods The randomized controlled trial methods were applied, and 80 ACI patients were randomly divided into treatment group and control group, 40 cases in each group. Two cases from each group were dropped out, and the left 38 cases of each group were included into the analysis. The control group was treated with the standardized western medicine regimen, and the treatment group was given BHD orally on the basis of treatment for the control group. The treatment for the two groups covered 7 days. On treatment day 3 and 7, TCD was adopted to investigate the blood flow velocity of the responsible vessels and the improvement of collateral circulation compensation. On treatment day 7, the scores of National Institute of Health Stroke Scale(NIHSS) in the two groups were compared. Results (1) On treatment day 3, collateral circulation improvement occurred in 12 patients(accounting for 31.58%)from the treatment group , and on treatment day 7 , the improved cases increased to 16(accounting for 42.11%). In the control group , 3 cases(7 . 89%) were improved on treatment day 3 , and 4(10 . 53%) improved on treatment day 7. The treatment group had better effect on improving collateral circulation than the control group, the difference being significant(P<0.01). (2) In the treatment group, 9 cases had increased blood flow velocity(Vm) of the responsible vessels on treatment day 3, and 11 cases had the increase on treatment day 7. In the control group, Vm increase occurred in one case both on treatment day 3 and 7. The treatment group had better effect on increasing Vm than the control group, the difference being significant(P<0.05). (3) On treatment day 7, NIHSS scores were decreased in both groups(P<0.05 or P<0.01), and the decrease of the treatment group was superior to that of the control group(P<0.01).(4) No adverse event was shown in the two g roups during the treatment. Conclusion BHD can constantly improve the blood flow velocity of the responsible vessel and promote collateral vessel building , which results into the recovery of the impaired neural function.

[Objective]To explore the regularity and characteristics of Zisheng Classic of Acupuncture and Moxibustion in the treatment of nasal diseases.[Methods]By combing the relevant provisions of Zisheng Classic of Acupuncture and Moxibustion on nasal diseases to systematically study,collate and summarize the number of acupoints,channel tropism,specific acupoint attributes and distribution rules,and analyze nasal diseases etiology and pathogenesis,treatment characteristics and the author's experience.[Results]A total of 66 acupoints were involved in the treatment of nasal diseases,and the total frequency of acupoints was 153 times.The top 3 use frequency of acupoints are Fengmen(BL12),Kouheliao(LI19)and Yinjiao(GV27),and the top 3 most used meridians are Foot-Taiyang bladder meridian,Du channel and Hand-Yangming large intestine meridian.The proportion of specific acupoints is the intersection point and the five Shu acupoints,which are mainly distributed in the head and limbs.The basic pathogenesis of nasal disease is attributed to deficiency of essential Qi and the pathogenic factors adhere to the exterior with severe symptoms.The treatment should emphasize on eliminating the stagnation,that is,to activate Yang Qi and nourish the mind,regulate Qi activity and clear the nasal orifice,warm the meridian points to regulate Qi and blood,making good use of prescription and medical records to increase authenticity.[Conclusion]Zisheng Classic of Acupuncture and Moxibustion not only reflects WANG Zhizhong's distinctive diagnosis and treatment characteristics for nasal diseases,but also summarizes WANG's academic thoughts on using the principle of eliminating the stagnation.To explore the regularity and characteristics of Zisheng Classic of Acupuncture and Moxibustion can provide new ideas and methods for the clinical treatment of nasal diseases.